Excision Biotherapeutics’ groundbreaking HIV treatment, EBT-101, was approved by the Food and Drug Administration to begin testing for its first phase of human trials. This new treatment relies on the Nobel Prize-winning, gene-editing technology CRISPR to successfully remove HIV proviral DNA from human cells. Scientists believe that this one-time treatment will “functionally cure” people from the virus, meaning only small traces of the HIV genome …
New Treatment EBT-101 Could Provide a Breakthrough Cure for HIV